NasdaqGS:QURE

Stock Analysis Report

Executive Summary

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has uniQure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QURE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.6%

QURE

3.6%

US Biotechs

-0.2%

US Market


1 Year Return

90.4%

QURE

11.0%

US Biotechs

16.1%

US Market

Return vs Industry: QURE exceeded the US Biotechs industry which returned 11% over the past year.

Return vs Market: QURE exceeded the US Market which returned 16.1% over the past year.


Shareholder returns

QUREIndustryMarket
7 Day-1.6%3.6%-0.2%
30 Day13.1%9.4%3.7%
90 Day-2.1%11.1%8.5%
1 Year90.4%90.4%12.0%11.0%18.7%16.1%
3 Year659.6%659.6%19.1%15.3%46.9%37.4%
5 Year245.7%245.7%6.1%1.2%61.8%44.0%

Price Volatility Vs. Market

How volatile is uniQure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is uniQure undervalued compared to its fair value and its price relative to the market?

6.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QURE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QURE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QURE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: QURE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QURE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QURE is overvalued based on its PB Ratio (6.1x) compared to the US Biotechs industry average (3x).


Next Steps

Future Growth

How is uniQure forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

23.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QURE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QURE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QURE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QURE's revenue (74.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: QURE's revenue (74.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QURE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has uniQure performed over the past 5 years?

-11.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QURE has high quality earnings.

Growing Profit Margin: QURE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QURE is unprofitable, and losses have increased over the past 5 years at a rate of -11.4% per year.

Accelerating Growth: Unable to compare QURE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QURE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: QURE has a negative Return on Equity (-30.4%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is uniQure's financial position?


Financial Position Analysis

Short Term Liabilities: QURE's short term assets ($407.6M) exceeds its short term liabilities ($28.4M)

Long Term Liabilities: QURE's short term assets ($407.6M) exceeds its long term liabilities (92.9M)


Debt to Equity History and Analysis

Debt Level: QURE's debt to equity ratio (10.3%) is considered satisfactory.

Reducing Debt: QURE's debt to equity ratio has reduced from 31.4% to 10.3% over the past 5 years.


Balance Sheet

Inventory Level: QURE has a low level of unsold assets or inventory.

Debt Coverage by Assets: QURE's debt is covered by short term assets (assets are 11.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QURE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: QURE has sufficient cash runway for 2.835492 years if free cash flow continues to reduce at historical rates of -1.3% each year.


Next Steps

Dividend

What is uniQure's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate QURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QURE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QURE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QURE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of uniQure's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Matt Kapusta (47yo)

2.9yrs

Tenure

US$4,095,328

Compensation

Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and serves as its Chief Financial Officer. Mr. Kapusta served as a Chief Financia ...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD4.10M) is about average for companies of similar size in the US market ($USD3.87M).

Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.6yrs

Average Tenure

52.5yo

Average Age

Experienced Management: QURE's management team is considered experienced (2.6 years average tenure).


Board Age and Tenure

2.7yrs

Average Tenure

57yo

Average Age

Experienced Board: QURE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: QURE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$224,90620 Sep 19
Robert Gut
EntityIndividual
Role
Member of the Board of Directors
Chief Medical Officer & Executive Director
Shares4,769
Max PriceUS$47.16
SellUS$88,40017 Apr 19
Christian Klemt
EntityIndividual
Role
Chief Accounting Officer
Chief Accounting Officer
Shares1,546
Max PriceUS$57.18
SellUS$15,503,71803 Apr 19
Coller Capital Ltd.
EntityCompany
Shares257,603
Max PriceUS$62.18
SellUS$37,88531 Jan 19
Jack Kaye
EntityIndividual
Shares1,210
Max PriceUS$31.31
SellUS$37,88530 Jan 19
Madhavan Balachandran
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares1,210
Max PriceUS$31.31
SellUS$37,89730 Jan 19
Paula Soteropoulos
EntityIndividual
Shares1,210
Max PriceUS$31.32
SellUS$37,88530 Jan 19
David Schaffer
EntityIndividual
Shares1,210
Max PriceUS$31.31
SellUS$37,89730 Jan 19
Philip Astley-Sparke
EntityIndividual
Role
Chairman of the Board
Chairman
Shares1,210
Max PriceUS$31.32
SellUS$42,51930 Jan 19
Sander van Deventer
EntityIndividual
Role
Top Key Executive
Co-Founder
Shares1,358
Max PriceUS$31.31
SellUS$46,27830 Jan 19
Christian Klemt
EntityIndividual
Role
Chief Accounting Officer
Chief Accounting Officer
Shares1,479
Max PriceUS$31.29
SellUS$32,91730 Jan 19
Alexander Kuta
EntityIndividual
Role
Chief Operating Officer
Executive Vice President of Operations
Shares1,052
Max PriceUS$31.29
SellUS$18,45730 Jan 19
Scott McMillan
EntityIndividual
Shares591
Max PriceUS$31.23
SellUS$37,89730 Jan 19
Jeremy Springhorn
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares1,210
Max PriceUS$31.32
SellUS$160,17507 Jan 19
Christian Klemt
EntityIndividual
Role
Chief Accounting Officer
Chief Accounting Officer
Shares5,739
Max PriceUS$27.91

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.


Management Team

  • Jon Garen (53yo)

    Chief Business Officer

    • Tenure: 3.3yrs
    • Compensation: US$1.32m
  • Matt Kapusta (47yo)

    CEO, CFO & Executive Director

    • Tenure: 2.9yrs
    • Compensation: US$4.10m
  • Sander van Deventer (65yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$129.40k
  • Tamara Tugal

    Business Development Director

    • Tenure: 11.4yrs
  • Maria Cantor (51yo)

    Senior Vice President of Investor Relations & Communication

    • Tenure: 3.4yrs
    • Compensation: US$1.22m
  • David Cerveny (52yo)

    Chief Legal Officer

    • Tenure: 1.7yrs
  • Alex Kuta (59yo)

    Executive Vice President of Operations

    • Tenure: 0.3yrs
    • Compensation: US$945.14k
  • Hugo Katus

    Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

    • Tenure: 5.3yrs
  • Christian Klemt (46yo)

    Chief Accounting Officer

    • Tenure: 2.3yrs
  • Robert Gut (55yo)

    Chief Medical Officer & Executive Director

    • Tenure: 1.4yrs
    • Compensation: US$19.99k

Board Members

  • Michael Hayden (68yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Philip Astley-Sparke (48yo)

    Chairman

    • Tenure: 3.2yrs
    • Compensation: US$254.42k
  • Matt Kapusta (47yo)

    CEO, CFO & Executive Director

    • Tenure: 2.9yrs
    • Compensation: US$4.10m
  • Kathy High (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jesús Prieto

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Robin Ali

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Madhu Balachandran (68yo)

    Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$204.32k
  • Jeremy Springhorn (57yo)

    Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$214.06k
  • Hugo Katus

    Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

    • Tenure: 5.3yrs
  • Robert Gut (55yo)

    Chief Medical Officer & Executive Director

    • Tenure: 1.4yrs
    • Compensation: US$19.99k

Company Information

uniQure N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: uniQure N.V.
  • Ticker: QURE
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.223b
  • Shares outstanding: 42.72m
  • Website: https://www.uniqure.com

Number of Employees


Location

  • uniQure N.V.
  • Paasheuvelweg 25a
  • Amsterdam
  • Noord-Holland
  • 1105 BP
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QURENasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDFeb 2014
0EE0LSE (London Stock Exchange)YesOrdinary SharesGBUSDFeb 2014

Biography

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase II ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/23 00:56
End of Day Share Price2019/11/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.